Brought to you by 
Biogen pays $200mm up front for Convergence, plus earn-outs
26 Aug 2020
Executive Summary
Enhancing its pain portfolio, Biogen Idec Inc. acquired closely held UK biotech Convergence Pharmaceuticals Ltd. for $200mm in cash up front plus up to $475mm in earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com